Company Website

Contact Information:

Hematology Contacts:
Florida: Julie Engroff
jengroff@gene.com
(415) 250-3519

Arizona: David Nadler
Nadler.David@gene.com
(602) 571-0430 

Rochester: Linda Schnell
Schnell.Linda@gene.com
(651) 785-3004 cell

Virtual Exhibit Hall Home

For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.

As your (new) Therapeutic Area Manager or TAM, I am responsible for Genentech's Hematology portfolio. I will serve as your primary point of contact and can:

• Provide the information you need about Gazyva (obinutuzumab) and Polivy (polatuzumab vedotin-piiq) and their approved indication to make decisions that support enhanced patient experience
• Deliver education to HCPs regarding product information, appropriate use, and dosing and administration based on FDA approved product information.

Please see the prescribing information for additional important safety information, including Boxed Warning.

Additional Information:
Gazyva (obinutuzumab) Prescribing Information
POLIVY (polatuzumab vedotin-piiq) Prescribing Information
Polivy Information
Gazyva FDA Approved Regimens
Genentech Patient Support Services